Compugen Reports Results Further Confirming CGEN-15049 as 'Promising' Target Candidate for Cancer Immunotherapy

By: via Benzinga
Compugen Ltd. (NASDAQ: CGEN) today disclosed results from recent studies further confirming CGEN-15049 as a promising target candidate ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.